Top-Rated StocksTop-RatedNASDAQ:IDYA IDEAYA Biosciences (IDYA) Stock Price, News & Analysis $42.39 +0.10 (+0.24%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$42.30▼$44.1150-Day Range$33.29▼$42.9052-Week Range$20.90▼$47.74Volume609,047 shsAverage Volume923,543 shsMarket Capitalization$3.21 billionP/E RatioN/ADividend YieldN/APrice Target$52.92 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get IDEAYA Biosciences alerts: Email Address IDEAYA Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside24.8% Upside$52.92 Price TargetShort InterestBearish15.85% of Float Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews Sentiment0.98Based on 8 Articles This WeekInsider TradingSelling Shares$4.83 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.26) to ($2.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.89 out of 5 starsMedical Sector227th out of 936 stocksPharmaceutical Preparations Industry99th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingIDEAYA Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 14 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIDEAYA Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about IDEAYA Biosciences' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.85% of the float of IDEAYA Biosciences has been sold short.Short Interest Ratio / Days to CoverIDEAYA Biosciences has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.Change versus previous monthShort interest in IDEAYA Biosciences has recently increased by 1.62%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIDEAYA Biosciences does not currently pay a dividend.Dividend GrowthIDEAYA Biosciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIDEAYA Biosciences has received a 72.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for IDEAYA Biosciences is -0.78. Previous Next 3.9 News and Social Media Coverage News SentimentIDEAYA Biosciences has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for IDEAYA Biosciences this week, compared to 4 articles on an average week.Search Interest3 people have searched for IDYA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows9 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IDEAYA Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,832,228.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of IDEAYA Biosciences is held by insiders.Percentage Held by Institutions98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IDEAYA Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($2.26) to ($2.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEAYA Biosciences is -21.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEAYA Biosciences is -21.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIDEAYA Biosciences has a P/B Ratio of 4.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about IDEAYA Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."Click here now to watch this exclusive interview About IDEAYA Biosciences Stock (NASDAQ:IDYA)IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Read More IDYA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IDYA Stock News HeadlinesJuly 20, 2024 | marketbeat.comMarketBeat Week in Review – 7/15 - 7/19 (IDYA)Stocks took a breather to close the week, but corporate earnings and the next reading on the PCE index will help determine what direction the market moves nextJuly 15, 2024 | marketbeat.comPositive News is Driving This Cancer Drug Maker's Stock HigherShares of IDEAYA Biosciences Inc. NASDAQ: IDYA are up more than 16% after announcing positive treatment data for its Phase 2 clinical trial. The company's pipeline candidate, IDE397, is an experimental drug designed to treat certain bladder and small-cell lung cancers.July 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.July 15, 2024 | marketbeat.comPositive News is Driving This Cancer Drug Maker’s Stock Higher (IDYA)IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breatherJuly 22, 2024 | americanbankingnews.comAnalysts Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Price Target at $52.92July 21, 2024 | americanbankingnews.comIDEAYA Biosciences (NASDAQ:IDYA) Trading 2.7% Higher July 19, 2024 | americanbankingnews.comIDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up to $41.35July 19, 2024 | americanbankingnews.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Sees Significant Increase in Short InterestJuly 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.July 19, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Issued By WedbushJuly 18, 2024 | americanbankingnews.comWedbush Reiterates Outperform Rating for IDEAYA Biosciences (NASDAQ:IDYA)July 11, 2024 | prnewswire.comIDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesJuly 9, 2024 | prnewswire.comIDEAYA Announces Pricing of Public OfferingJuly 9, 2024 | prnewswire.comIDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJuly 8, 2024 | investopedia.comIDEAYA Biosciences Soars on Cancer Drug Study ResultsJuly 8, 2024 | seekingalpha.comIdeaya Biosciences: Poised For Success In Bladder And Lung Cancer?July 8, 2024 | prnewswire.comIDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung CancerJuly 5, 2024 | prnewswire.comIDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024See More Headlines Receive IDYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IDYA CUSIPN/A CIK1676725 Webwww.ideayabio.com Phone(650) 443-6209FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$52.92 High Stock Price Target$69.00 Low Stock Price Target$33.00 Potential Upside/Downside+24.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,960,000.00 Net Margins-483.05% Pretax Margin-831.30% Return on Equity-20.09% Return on Assets-19.30% Debt Debt-to-Equity RatioN/A Current Ratio28.42 Quick Ratio28.42 Sales & Book Value Annual Sales$23.39 million Price / Sales137.17 Cash FlowN/A Price / Cash FlowN/A Book Value$9.64 per share Price / Book4.40Miscellaneous Outstanding Shares75,690,000Free Float73,038,000Market Cap$3.21 billion OptionableOptionable Beta0.86 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Yujiro S. Hata (Age 50)President, CEO & Director Comp: $912kMr. Andres Ruiz Briseno CPA (Age 38)Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations Comp: $485.12kDr. Michael A. White Ph.D. (Age 58)Chief Scientific Officer Comp: $661.8kMr. Jason S. Throne Esq. (Age 52)J.D., Chief Legal Officer & Company Secretary Comp: $598.8kDr. Darrin M. Beaupre M.D. (Age 57)Ph.D., Chief Medical Officer Comp: $665.58kDr. Paul A. Barsanti Ph.D.Chief Technology OfficerMr. Mick O'QuigleyChief of Staff & Clinical DevelopmentMore ExecutivesKey CompetitorsCatalyst PharmaceuticalsNASDAQ:CPRXSyros PharmaceuticalsNASDAQ:SYRSOsmotica PharmaceuticalsNASDAQ:OSMTCue BiopharmaNASDAQ:CUETherapeuticsMDNASDAQ:TXMDView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 95,129 shares on 7/26/2024Ownership: 0.418%Legato Capital Management LLCSold 5,697 shares on 7/26/2024Ownership: 0.012%China Universal Asset Management Co. Ltd.Sold 5,454 shares on 7/20/2024Ownership: 0.012%Nisa Investment Advisors LLCBought 927 shares on 7/20/2024Ownership: 0.004%SG Americas Securities LLCBought 9,472 shares on 7/12/2024Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions IDYA Stock Analysis - Frequently Asked Questions How have IDYA shares performed this year? IDEAYA Biosciences' stock was trading at $35.58 on January 1st, 2024. Since then, IDYA stock has increased by 19.1% and is now trading at $42.39. View the best growth stocks for 2024 here. How were IDEAYA Biosciences' earnings last quarter? IDEAYA Biosciences, Inc. (NASDAQ:IDYA) posted its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.02. The firm's quarterly revenue was down 100.0% compared to the same quarter last year. When did IDEAYA Biosciences IPO? IDEAYA Biosciences (IDYA) raised $70 million in an initial public offering on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO. Who are IDEAYA Biosciences' major shareholders? Top institutional investors of IDEAYA Biosciences include Bank of New York Mellon Corp (0.42%), SG Americas Securities LLC (0.02%), Legato Capital Management LLC (0.01%) and China Universal Asset Management Co. Ltd. (0.01%). Insiders that own company stock include Yujiro S Hata, Briseno Andres Ruiz, Paul A Stone, Michael Anthony White, Jason Throne and Michael P Dillon. View institutional ownership trends. How do I buy shares of IDEAYA Biosciences? Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of IDEAYA Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA) and Xeris Biopharma (XERS). This page (NASDAQ:IDYA) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
